Comparison · NCT04157348-fe979874
Benralizumab 30 mg vs Mepolizumab 300 mg: Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Benralizumab 30 mg vs Mepolizumab 300 mg: Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48. Trial comparisons, record NCT04157348-fe979874. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04157348-fe979874
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.571 | 0.455 | 0.681 | wilson | |
| Risk in group 2 | 0.571 | 0.455 | 0.681 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.16 | 0.16 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1 | 0.751 | 1.33 | log | |
| Odds ratio, group 1 over group 2 | 1 | 0.512 | 1.95 | log | |
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Benralizumab 30 mg | Benralizumab and matching placebo injections delivered subcutaneously every 4 weeks | 40 | 70 | OG000 |
| Group 2 | Mepolizumab 300 mg | Mepolizumab and matching placebo injection delivered subcutaneously every 4 weeks | 40 | 70 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48
- Description
- Percentage of patients with relapsing or refractory EGPA, achieving remission, defined as BVAS = 0 and OCS dose ≤ 4 mg/day (main remission definition) at both Weeks 36 and 48.
- Time frame
- Week 36 and Week 48
- Population
Full Analysis Set: All patients randomized and receiving at least one (1) dose of IP are included in the full analysis set, irrespective of their protocol adherence and continued participation in the study.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
- NCT number
- NCT04157348
- Phases
- PHASE3
- Conditions
- Eosinophilic Granulomatous Vasculitis
- Interventions
- Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
- Lead sponsor
- AstraZeneca
- Results first posted
- 2025-01-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04157348?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04157348-fe979874